<?xml version="1.0" encoding="UTF-8"?>
<p id="par0070">On the other hand, we reviewed 26 guidelines from Chinese local governments: local government guidelines were available from all 17 provinces, with 4 cities under the direct control of the central government, and 4 autonomous districts. However, despite the existence of guidelines from the central government, the local guidelines have varied significantly: for instance, we noticed a tendency in Sichuan province wherein people refrained from using Mahuang (
 <italic>Ephedra sinica</italic>) as much as possible (in general, it has been noted that people from the Southern provinces do not prefer strong medicines). Another characteristic we noticed was that these guidelines were distributed in a top-down format, without any consensus among experts. In Korea, KMDs cannot see COVID-19 patients who require hospitalization because of various reasons, including political and regulatory issues and thus, we cannot provide any KM treatments for those patients. After many twists and turns, the Association of Korean Medicine submitted a KM guideline for COVID-19, which was comprehensively constructed by relevant societies and experts.
 <xref rid="bib0035" ref-type="bibr">
  <sup>7</sup>
 </xref> Moreover, I separately worked on the treatment guidelines at the Division of Respiratory Medicine in Korean Society of Oriental Internal Medicine.
 <xref rid="bib0040" ref-type="bibr">
  <sup>8</sup>
 </xref> In that guideline, CheongPyeBaeDok decoction without coltsfoot was suggested as the primary prescription, considering the roles of various herbs. In addition to CheongPyeBaeDok decoction, other prescriptions were recommended based on the insurance covered items via the standard process of guideline development.
</p>
